Regnase-1敲除对脐血来源CAR-T细胞的生物学功能影响  被引量:1

The Effect of Regnase-1 Knockout on the Function of Cord Blood-Derived CAR-T Cells

在线阅读下载全文

作  者:刘佳慧 冉凤萍 蒙露 赵日 李华 LIU Jiahui;RAN Fengping;MENG Lu;ZHAO Ri;LI Hua(School of Basic Medicine,Chengdu University of Traditional Chinese Medicine,Chengdu 610075,China;Department of Oncology,Western Theater General Hospital,Chengdu 610083,China;Department of Gynaecology and Obstetrics,Chengdu BOE hosptial,Chengdu 610200,China;Scientific Research and Experimental Center,Chengdu Medical College,Chengdu 610500,China;Medical College of Southwest Jiaotong University,Chengdu 610031,China)

机构地区:[1]成都中医药大学,基础医学院,成都610075 [2]西部战区总医院,肿瘤科,成都610083 [3]成都京东方医院,妇产科,成都610200 [4]成都医学院,科研实验中心,成都610500 [5]西南交通大学,医学院,成都610031

出  处:《中国细胞生物学学报》2023年第10期1473-1481,共9页Chinese Journal of Cell Biology

基  金:四川省科技厅应用基础研究项目(批准号:19YYJC0242)资助的课题。

摘  要:嵌合抗原受体T(chimeric antigen receptor-T,CAR-T)细胞治疗虽然在血液肿瘤治疗中疗效显著,但仍面临CAR-T细胞体内持续性短的问题,后者与疗效密切相关。Regnase-1具有核糖核酸酶作用,负向调控免疫应答。该研究在脐血T(cord blood T)细胞上成功敲除Regnase-1,制备Regnase-1缺陷的靶向CD19的脐血CAR-T细胞Regnase-1-CAR-T,发现敲除Regnase-1不影响脐血T细胞表达CAR分子,也不影响CAR-T细胞体外增殖和分化,在CAR-T体外生长早期可显著抑制CD39耗竭分子,并且显著增强CAR-T特异性持续杀伤能力和扩增能力,有助于改善脐血CAR-T细胞持续性,为CAR-T细胞药物的优化奠定基础。Although CAR-T(chimeric antigen receptor-T)cell therapy is effective in the treatment of hematologic tumors,it still faces the problem of short persistence of CAR-T cells in vivo,which is closely related to the clinical efficacy.Regnase-1 has a ribonuclease effect and negatively regulates the immune response.In this study,regnase1-deficient CAR-T cells delivered from cord blood T cells were prepared.The Regnase-1 deletion did not affect either the expression of CAR molecules of cord blood T cells or the proliferation or the differentiation of CAR-T cells in vitro.CD39,an exhausted T cell marker,could be significantly inhibited at the early stage of CAR-T growth in vitro.Regnase-1 kncokout enhanced the specific killing ability and increased amplication of CAR-T,which helps to improve cord blood-derived CAR-T cell persistence and lays a foundation for the optimization of CAR-T cell drugs.

关 键 词:Regnase-1 脐带血 CAR-T细胞治疗 

分 类 号:R392[医药卫生—免疫学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象